☰

Mikael Rinne, Ph.D. - Publications

Affiliations: 
2004 Indiana University, Bloomington, Bloomington, IN, United States 
Area:
Molecular Biology, Cell Biology, Oncology
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Nayak L, Hays J, Muzikansky A, Gaffey S, Do K, Hilton J, Lee E, Rinne M, Norden A, Beroukhim R, Puduvalli V, Wen P, Doyle LA, Chen H, Shapiro G, et al. Atnt-18A Phase I Study Of Mln0128 And Bevacizumab In Patients With Recurrent Glioblastoma And Other Solid Tumors Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov205.18  0.315
2014 Lee E, Reardon D, Schiff D, Drappatz J, Muzikansky A, Grimm S, Norden A, Nayak L, Beroukhim R, Rinne M, Chi A, Batchelor T, Hempfling K, McCluskey C, Smith K, et al. At-36Panobinostat In Combination With Bevacizumab For Recurrent Glioblastoma And Anaplastic Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.36  0.304
2014 Wen PY, Wen PY, Yung WKA, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, et al. PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM Neuro-Oncology. 16: iii47-iii47. DOI: 10.1093/Neuonc/Nou209.20  0.344
2013 Wen PY, Yung WKA, Mellinghoff IK, Lamborn K, Ramkissoon S, Cloughesy TF, Rinne M, Omuro AMP, DeAngelis LM, Gilbert MR, Chi AS, Batchelor T, Colman H, Chang SM, Massacesi C, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). Journal of Clinical Oncology. 31: 2015-2015. DOI: 10.1200/Jco.2013.31.15_Suppl.2015  0.332
2007 Harrison JF, Rinne ML, Kelley MR, Druzhyna NM, Wilson GL, Ledoux SP. Altering DNA base excision repair: use of nuclear and mitochondrial-targeted N-methylpurine DNA glycosylase to sensitize astroglia to chemotherapeutic agents. Glia. 55: 1416-25. PMID 17674369 DOI: 10.1002/Glia.20556  0.476
2005 Rinne ML, He Y, Pachkowski BF, Nakamura J, Kelley MR. N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts. Nucleic Acids Research. 33: 2859-67. PMID 15905475 DOI: 10.1093/Nar/Gki601  0.502
2004 Kremer TM, Rinne ML, Xu Y, Chen XM, Kelley MR. Protection of pulmonary epithelial cells from oxidative stress by hMYH adenine glycosylase. Respiratory Research. 5: 16. PMID 15450125 DOI: 10.1186/1465-9921-5-16  0.461
2004 Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Molecular Cancer Therapeutics. 3: 955-67. PMID 15299078  0.514
2004 Rinne M, Caldwell D, He Y, Kelley MR. 282. Transient Adenoviral Methylpurine DNA Glycosylase Overexpression Imparts Chemotherapeutic Sensitivity to Human Breast Cancer Cells Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.220  0.535
Show low-probability matches.